| Name | Title | Contact Details |
|---|
Leveraging the power of claims data from more than 200 million Americans, Blue Health Intelligence® (BHI®) delivers insights that empower healthcare organizations to improve patient care, reduce costs, and optimize performance. With the largest, most up-to-date, and uniform data set in healthcare, BHI provides an accurate representation of the health profile of commercially insured Americans. BHI is a trade name of Health Intelligence Company, LLC, an independent licensee of the Blue Cross Blue Shield Association.
SantenUSA.com - a specialty pharmaceutical offering ophthalmic products & research for retinal disorders, glaucoma, and other eye diseases.
We are Salience Learning. We help solve life science’s most complex business challenges by delivering transformative learning experiences.
Affinium Pharmaceuticals , Inc. is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Albireo Pharma is a clinical-stage biopharmaceutical company focused through its operating subsidiary on the development of novel bile acid modulators to treat orphan pediatric liver diseases, and other liver and gastrointestinal diseases and disorders. Albireo`s lead product candidate, A4250, is directed to treat rare pediatric cholestatic liver diseases and is in Phase 3 development in its initial target indication, progressive familial intrahepatic cholestasis. Albireo`s clinical pipeline also includes two Phase 2 product candidates. Albireo`s elobixibat, approved in Japan for the treatment of chronic constipation, is the first ileal bile acid transporter (IBAT) inhibitor approved anywhere in the world. Albireo was spun out from AstraZeneca in 2008. Albireo Pharma is located in Boston, Massachusetts, and its key operating subsidiary is located in Gothenburg, Sweden.